Loading...
01/11 03:36
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals: strong adjusted EBITDA growth and improved cash flow are positive, but concerns about tariffs, economic uncertainty, and workforce transition risks persist. The Q&A section highlights management's vague responses on cost savings and policy impacts, adding to uncertainty. Despite positive financial performance, lack of shareholder returns and unclear guidance on strategic initiatives balance the sentiment, leading to a neutral prediction.
Adjusted EBITDA $18,200,000, nearly doubled from $10,000,000 year-over-year, with a margin of 20.9%, up 860 basis points due to revenue growth and expense management.
Cash Flow from Operations $5,400,000, an increase of $7,400,000 compared to negative $2,000,000 year-over-year, attributed to improved working capital management.
Net Leverage Ratio 2.4 times, down from 4.4 times year-over-year, reflecting improved debt repayment and operational performance.
Revenue $87,200,000, a 3.7% increase year-over-year; normalizing for divestiture impacts, revenue would have been up 6.5%.
Gross Margins 54.7%, increased by 430 basis points year-over-year, driven by growth in financial health and reduced labor costs.
Operating Expenses $39,500,000, representing 45.3% of total revenue, down from 51.1% year-over-year due to cost optimization actions.
Bookings $22,000,000, down from $24,000,000 year-over-year, with a shift to annual contract value (ACV) reporting.
Accounts Receivable Down 12% year-over-year, contributing to improved cash flow and working capital management.
Days Sales Outstanding (DSO) Improved by 12 days year-over-year, indicating better collection efficiency.
New SaaS Offerings: Introduced a tiered SaaS package inclusive of EHR offerings, not based on collection volumes.
EHR Solutions: Signed two new customers transitioning from paper-based systems to EHR solutions.
Market Expansion: Secured two deals in the 100 to 400 bed hospital market segment, demonstrating a land and expand strategy.
Customer Retention: Achieved a 98% customer retention rate in patient care, excluding Sentric.
Operational Efficiency: Improved cash flow from operations to $5,400,000, a $7,400,000 increase year-over-year.
Workforce Transition: Aiming for 60% of CVO clients supported offshore by the end of 2025.
Strategic Shift: Transitioning to reporting bookings on an annual contract value (ACV) basis to enhance clarity.
Investment in Automation: Plans to accelerate innovation in financial health to automate workflows, responding to demand for AI.
Regulatory Risks: Ongoing uncertainty related to future healthcare funding and potential changes to Medicare expansion and reimbursement policies may cause customers to slow down their decision-making processes.
Competitive Pressures: The company faces competitive pressures in the healthcare market, particularly in the EHR space, where the shift to SaaS models has changed the dynamics of revenue recognition.
Supply Chain Challenges: Potential impacts of tariffs on U.S. businesses could affect hospital budgets, leading to a more cautious approach in capital allocation by customers.
Operational Risks: Elevated levels of customer satisfaction challenges and the need to attract and retain the right talent, both domestically and offshore, are critical for maintaining service quality.
Economic Factors: General economic uncertainty may impact customer spending and investment in new technologies, affecting the company's growth and revenue projections.
Workforce Transition Risks: The transition to a more automated and offshore workforce may present challenges in maintaining service quality and employee productivity.
Bookings: Q1 bookings totaled $22,000,000, with a 50% sequential increase in financial health bookings and a 60% sequential increase in patient care bookings.
Customer Retention: Customer retention for patient care stands at 98%, showing improvement compared to the previous year.
Operational Initiatives: Plans to standardize global hiring processes and establish a centralized workplace to streamline operations.
Automation: Plans to accelerate innovation in financial health by responding to demand for automation in revenue cycle improvements.
SaaS Offerings: Introduced new tiered SaaS packages and TruBridge Analytics to enhance customer offerings.
Revenue Guidance: Maintaining revenue expectations for 2025 between $345,000,000 and $360,000,000.
Adjusted EBITDA Guidance: Increasing adjusted EBITDA range to $60,000,000 to $66,000,000, up from previous range of $59,000,000 to $66,000,000.
Q2 Revenue Expectations: Q2 revenue expected to decrease from Q1 due to timing of revenue recognition.
Q2 Adjusted EBITDA Expectations: Sequential step down in adjusted EBITDA expected due to annual user conference costs and timing of revenue.
Share Repurchase Program: None
Dividend Program: None
The earnings call indicates a negative sentiment due to several factors: decreased sand sales volumes and revenue, higher operating expenses, and economic uncertainties affecting completion activities. Although there's a share repurchase program, the overall financial performance is weak, with lower EBITDA and increased costs. The Q&A section reveals uncertainty in future guidance, further dampening sentiment. The revised revenue guidance and increased costs suggest a negative impact on the stock price in the short term.
The earnings call showed mixed results: improved cash flow and debt reduction are positives, but revenue growth is modest. The Q&A highlighted delays in bookings and uncertainties in Medicaid funding. While guidance was revised, the EBITDA outlook is stronger. However, the lack of specific guidance details and potential delays temper enthusiasm. Overall, the stock is likely to remain stable, reflecting a neutral sentiment.
The earnings call shows a generally positive outlook with several key highlights: strong customer retention, increased gross margins, and an increase in bookings. While financial health revenue remained flat, patient care revenue showed growth. Management's confidence in maintaining consistent bookings and addressing retention issues is promising. The Q&A section reveals some concerns about client attrition and potential headwinds from new legislation, but the overall sentiment remains optimistic with strategic plans for growth and efficiency improvements.
The earnings call reveals mixed signals: strong adjusted EBITDA growth and improved cash flow are positive, but concerns about tariffs, economic uncertainty, and workforce transition risks persist. The Q&A section highlights management's vague responses on cost savings and policy impacts, adding to uncertainty. Despite positive financial performance, lack of shareholder returns and unclear guidance on strategic initiatives balance the sentiment, leading to a neutral prediction.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
